RxDoctor Payments Data

Heather Gray, PA

Medical · Lander, WYNPI 1568645885

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.5% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $599 and has fallen 84.0% since, to $96 in 2025.

$1,848in general payments, 2019–2025

Across 104 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$385
  • Lilly USA, LLC$185
  • Amgen$150
  • Novo Nordisk$124
  • Biohaven Pharmaceutical Holding Company Ltd.$115
  • Astellas Pharma US Inc$104
  • plus $784 from 24 others

What the payments were for

  • Food & beverage$1,82199%
  • Other$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,848 in reported general payments places this provider in the 80th percentile of 56 medical providers in Wyoming.

See all medical providers in Wyoming

Medicare billing

Part B allowed, 2024
$9,374
Medicare patients
56
Services billed
183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,335
Gabapentin35$1,130
Omeprazole32$941
Levothyroxine Sodium50$551
Pravastatin Sodium16$512
Atorvastatin Calcium68$458
Oxybutynin Chloride ErOxybutynin Chloride20$437
Lisinopril56$354
Rosuvastatin Calcium26$313
Albuterol Sulfate HfaAlbuterol Sulfate19$271
Pantoprazole Sodium19$226
Famotidine12$225
Escitalopram Oxalate18$213
Tamsulosin Hcl19$203
Potassium Chloride11$202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$26$9,33514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 56 medical providers in Wyoming.

Other medical in Lander

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →